Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

The primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MTD) of the potent and selective Aurora B kinase inhibitor barasertib (AZD1152) in patients with newly diagnosed or relapsed acute myeloid leukemia (AML). Part A determined the MTD of barasertib adminis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Löwenberg, Bob, Muus, Petra, Ossenkoppele, Gert, Rousselot, Philippe, Cahn, Jean-Yves, Ifrah, Norbert, Martinelli, Giovanni, Amadori, Sergio, Berman, Ellin, Sonneveld, Pieter, Jongen-Lavrencic, Mojca, Rigaudeau, Sophie, Stockman, Paul, Goudie, Alison, Faderl, Stefan, Jabbour, Elias, Kantarjian, Hagop
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2011
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186639/
https://ncbi.nlm.nih.gov/pubmed/21976672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-366930
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars